Home > Search Results

Results: 9

Lisdexamfetamine Dimesylate -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of lisdexamfetamine as part of a comprehensive treatment programme for attention deficit / hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate, in comparison with the appropriate comparator therapy (ACT) atomoxetine.

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: August 29, 2013

Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents

Bibliographic details: Mattos P.  Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents. Revista de Psiquiatria Clinica 2014; 41(2): 34-39

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Treatment Options for ADHD in Children and Teens: A Review of Research for Parents and Caregivers

This summary discusses the different types of treatment for ADHD. It explains what research says about how each treatment improves symptoms and the risks involved with each treatment. It can help you talk with the doctor about ADHD and your child.

Comparative Effectiveness Review Summary Guides for Consumers [Internet] - Agency for Healthcare Research and Quality (US).

Version: June 26, 2012

Management and Outcomes of Binge-Eating Disorder [Internet]

To evaluate the effectiveness and comparative effectiveness of treatments for patients with binge-eating disorder (BED) and bariatric surgery patients and children with loss-of-control (LOC) eating. Studies of BED therapies include pharmacological interventions, psychological and behavioral interventions, or combinations of approaches. We examined whether treatment effectiveness differed in patient subgroups and described course of illness for BED and LOC eating.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: December 2015
Show search results within this document

High-dose Stimulants for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]

This review considers the use of short, intermediate, and/or long acting stimulants, such as, methylphenidate, amphetamine, dextro-amphetamine, and lisdexamfetamine, in children and adults. Many persons with attention-deficit/hyperactivity disorder (ADHD) require individualized, optimal dose-titration to address symptoms, and it is recommended that patients start on the lowest possible dose and titrate upwards to appropriately manage symptoms. This review aims to address concerns regarding the effectiveness and safety of the use of stimulants at higher than recommended doses.

Rapid Response Report: Summery With Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: March 3, 2016
Show search results within this document

Guidelines and Recommendations for ADHD in Children and Adolescents [Internet]

Medications to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are available in short- and long-acting formulations. Short-acting formulations of methylphenidate (e.g., Ritalin) and dextroamphetamine (e.g., Dexedrine) are generally given two to three times daily. They have been shown to be effective in reducing ADHD symptoms and provide dosing flexibility. Compared with short-acting formulations, long-acting formulations are given less frequently, but are more expensive and are not covered in all insurance plans. Recommendations about the use of long- or short-acting formulations are largely derived from expert opinion of best practices. Discourse on the use of long-acting formulations have centred on the following issues: compliance, social stigma, in-school dosing, and drug diversion.

Rapid Response Report: Summary of Current Evidence - Canadian Agency for Drugs and Technologies in Health.

Version: October 2011
Show search results within this document

Pharmacologic Management of Patients with ADHD: A Review of Guidelines [Internet]

The aim of this review is to summarize recommendations for the pharmacotherapy of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults from current evidence-based clinical guidelines to support treatment decisions.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: March 18, 2016
Show search results within this document

Guanfacine Hydrochloride Extended Release (Intuniv XR) Tablets: For the Treatment of Attention-Deficit/Hyperactivity Disorder [Internet]

The objective of this review was to compare the clinical benefits and harms of guanfacine extended release (GXR; brand name: Intuniv XR) with those of other active treatments and placebo in children aged six to 12 years with attention-deficit/hyperactivity disorder (ADHD).

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: July 2015
Show search results within this document

Fatigue (PDQ®): Health Professional Version

Expert-reviewed information summary about fatigue, a condition marked by extreme tiredness and inability to function because of lack of energy, often seen as a complication of cancer or its treatment.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: January 13, 2017

Systematic Reviews in PubMed

See all (20)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...